Search
Sumario de resultados
TIpos de contenido
Fecha
-
Press releaseThe european bioeconomy urges the EC to harmonize policies, strengthen funding, and create...
The European project ShapingBio, of which AseBio is a partner, has presented a report with key recommendations for the upcoming EU Bioeconomy Strategy, aimed at driving a more sustainable, circular
-
New#BIOSPAIN2025 | “A key platform to connect with industry leaders, explore collaboration op...
Jordi Gibert Amat, Head of the Biotechnology Business Unit at Klinea Biotech & Pharma Engineering, Platinum Sponsor of BIOSPAIN 2025, analyzes the contribution of biotechnology to the pharmaceutical
-
New#NewAseBioMember | “AseBio is the meeting point and driving force behind biotechnology in ...
Meet Danae UroGenomics, our new member. We spoke with Marta Dueñas, Founder.
-
NewGenetics applied to healthy aging becomes a reality with N-GENE
Various studies estimate that genetic factors explain between 20–30% of the variability in lifespan.
-
NewHow TruSight Oncology 500 v2 is helping advance cancer research at the Catalan Institute o...
Líder mundial en genómica, Illumina ofrece soluciones integrales de secuenciación de nueva generación en los ámbitos clínicos, de investigación y de aplicaciones.
-
NewKlinea is a B Corp
The engineering solutions development company for the pharmaceutical and biotechnology sector is clear that the future of the industry must be built on a strong commitment to sustainability values.
-
NewBiohope presents the results of the BIOTRAIM study on the use of pretransplant Immunobiogr...
Immunobiogram® is a test that measures in vitro the sensitivity (response) of each patient's immune system cells to immunosuppressive drugs, with the aim of facilitating the personalization of
-
NewORYZON receives European Medicines Agency approval to initiate a Phase Ib study of iadadem...
First iadademstat clinical trial in non-malignant hematological indications.
-
NewFlomics Biotech joins Eurostars project LUMINA to advance lung cancer recurrence detection...
The project, which launched on June 1, 2025, aims to develop an innovative platform for the non-invasive detection of minimal residual disease (MRD) in lung cancer patients using multi-omic biomarkers
-
-
EventBIO Europe 2025 Austria
-
CompanyOlavide Neuron STX S.L. (ONESTX)
-
CompanyDanae UroGenomics S.L.
-
-
NewNew milestone for Mikrobiomik: recruits first patient in its LiverGut Phase III trial for ...
The biotechnology company Mikrobiomik has begun patient recruitment for LiverGut, the first clinical trial in Europe to evaluate an oral therapy based on gut microbiota aimed at slowing the
-
NewORYZON reports financial results and corporate update for half-year ending June 30, 2025
Between December 2024 and July 2025, Oryzon secured financing totaling €52 M, approx. $61 M (€30.0 M from a capital increase, €7.0 M from commercial bank loans, €13.2 M from the EU-IPCEI grant, and €1
-
NewInveready successfully closes Inveready Innvierte Biotech II, its second life sciences fun...
Inveready completes its third venture capital fund with a 4.3x return on capital invested by shareholders
-
NewMikrobiomik launches a Capital Cell funding campaign to support its next clinical trial
Mikrobiomik launches a Capital Cell funding campaign to support its next clinical trial
-
NewEHDS: A revolution in health data management
The European Health Data Space (EHDS) is conceived as a federated, interoperable, secure and privacy-focused infrastructure, integrating health data generated in all Member States.
-
NewNew technology detects breast cancer relapse up to five years before symptoms appear using...
A study led by Dr. Iñaki Comino-Méndez and Dr. Emilio Alba from the Hospital Universitario Virgen de la Victoria of Málaga/IBIMA and Dr. Ángel Guerrero-Zotano from the Instituto Valencia de Oncología
-
New#NewAseBioMember | “AseBio represents the meeting point of Spain’s biotechnology ecosystem...
Meet our new member, Genomcore. We spoke with Miquel A. Bru, Cofounder & CBDO.
